OCUL is expected to report earnings to rise+50% to -18 cents per share on May 07

A.I.dvisor
at Tickeron.com
05/06/24
Loading...
OCUL - Ocular Therapeutix
Ocular Therapeutix Earnings Graph
Q1'24
Est.
$-0.18
Q4'23
Missed
by $0.05
Q3'23
Beat
by $0.04
Q2'23
Beat
by $0.04
Q1'23
Missed
by $0.13
The last earnings report on December 31 showed earnings per share of -35 cents, missing the estimate of -30 cents. P/B Ratio (10.471) is normal, around the industry mean (10.296). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). OCUL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). OCUL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (9.033) is also within normal values, averaging (233.055). With 4.64M shares outstanding, the current market capitalization sits at 954.66M.
View a ticker or compare two or three
OCULDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
15 Crosby Drive
Phone
+1 781 357-4000
Employees
267
Web
https://www.ocutx.com